Abstract
Currently, the climate surrounding medicinal cannabis and its derived products is filled with both enthusiasm from patients and physicians searching for novel treatments and uncertainty due to conflicting laws between federal and state governments. Under the Controlled Substances Act (CSA) enacted by Congress in 1970, cannabis and cannabis-derived products are classified as Schedule I drugs, which indicates a lack of accepted medical use for the drug and enacts strict regulations on possession, manufacturing, dispensing, and clinical research involving these substances. Despite federal regulations, the use of cannabis for medical purposes has moved mainstream with nearly all US states decriminalizing either cannabis or cannabis-derived products (cannabinoids) for specific medicinal purposes. This chapter aims to provide physicians and other healthcare providers with an up-to-date understanding of the current legal framework surrounding medical cannabis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hoffmann DE, Weber E. Medical marijuana and the law. N Engl J Med. 2010;362(16):1453–7. https://doi.org/10.1056/nejmp1000695.
Annas GJ. Medical marijuana, physicians, and state law. N Engl J Med. 2014;371(11):983–5. https://doi.org/10.1056/nejmp1408965.
Mead A. Legal and regulatory issues governing cannabis and cannabis-derived products in the united states. Front Plant Sci. 2019;10:697. https://doi.org/10.3389/fpls.2019.00697.
Mead A. The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law. Epilepsy Behav. 2017;70:288–91. https://doi.org/10.1016/j.yebeh.2016.11.021.
Drug Enforcement Administration. Denial of petition to initiate proceedings to reschedule marijuana. Administration DE, editor. 81 Fed. Reg; 2016. p. 53699.
Boehnke KF, Gangopadhyay S, Clauw DJ, Haffajee RL. Qualifying conditions of medical cannabis license holders in the United States. Health Aff. 2019;38(2):295–302. https://doi.org/10.1377/hlthaff.2018.05266.
Milley J. Which states do not require medical marijuana testing and why not, 2018? 2018. Available at: https://droseaz.com/which-states-do-not-require-medical-marijuana-testing-and-why-not/. Accessed 5 Jan 2020.
FDA regulation of cannabis and cannabis-derived products, including cannabidiol (CBD). (8/3/2020). https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd#approved. Accessed 31 Aug 2020.
Rep. Gaetz, Matt. H.R.601 – 116th congress (2019-2020): Medical Cannabis Research Act of 2019. https://www.congress.gov/bill/116th-congress/house-bill/601?q={“search”:[“medical+cannabis+research+act”]}. Accessed 31 Aug 2020.
Senator Feinstein, Dianne S. 2032 – 116th congress (2019–2020): Cannabidiol and Marihuana Research Expansion Act, 2019. https://www.congress.gov/bill/116th-congress/senate-bill/2032/text?r=11. Accessed 31 Aug 2020.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Eshraghi, Y., Duracher, D. (2021). Cannabis Regulations. In: Narouze, S.N. (eds) Cannabinoids and Pain. Springer, Cham. https://doi.org/10.1007/978-3-030-69186-8_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-69186-8_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-69185-1
Online ISBN: 978-3-030-69186-8
eBook Packages: MedicineMedicine (R0)